---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacokinetics"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacokinetics. Topics: Absorption and time to peak concentration; Dose proportionality; Accumulation, peak-to-trough fluctuation, and effective half-life; Terminal half-life; 12 further topics. 16 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Absorption and time to peak concentration

> “Single-dose and steady-state PK analyses (cycles 1 and 2, day 1) showed that palazestrant was readily bioavailable and demonstrated rapid absorption with a median Tmax of approximately 4 h”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-2"></a>

### Dose proportionality

> “Palazestrant also showed linear PK with a dose-proportional exposure in the dose range of 30 mg/day to 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-3"></a>

### Accumulation, peak-to-trough fluctuation, and effective half-life

> “Steady-state PK profiles showed limited peak-to-trough fluctuation (range, 1.89–2.51), with an accumulation ratio of approximately 3 for Cmax (range, 1.96–3.55) and of approximately 4 for AUC0–24 (range, 3.63–5.20), and an effective half-life of approximately 70 h (range, 50.5 h to 77.2 h).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-4"></a>

### Terminal half-life

> “Overall, palazestrant showed biphasic elimination in the distribution phase, which was similar to that observed with 120 mg palazestrant in healthy volunteers (data on file), confirming the 8-day terminal half-life.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-5"></a>

### Distribution and support for once-daily dosing

> “PK analyses showed that palazestrant was readily bioavailable and rapidly absorbed (reaching peak concentration after 4 h), with extensive tissue distribution, dose-proportional exposure, and a long half-life of approximately 8 days. These PK characteristics support once-daily dosing.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-6"></a>

### Steady-state exposure at the recommended phase 2 dose

> “The steady-state geometric mean AUC0–24 was 4030 and 9210 h*ng/mL for 60 and 120 mg dose cohorts, respectively”
> “At the RP2D of 120 mg (n = 73), the geometric mean Cmax at steady state was 541 ng/mL, and the geometric mean Cavg was 384 ng/mL, showing sustained concentrations above the predicted efficacy threshold”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-7"></a>

### Steady-state pharmacokinetic parameters at 60, 90, and 120 mg

| Dose, once daily | Tmax,ss, h, median [min–max] | Cmin,ss, ng/mL, GeoMean (GeoCV%) | Cmax,ss, ng/mL, GeoMean (GeoCV%) | Cavg,ss, ng/mL, GeoMean (GeoCV%) | AUC0–24,ss, ng*h/mL, GeoMean (GeoCV%) | Accumulation ratio, Cmax,ss | Accumulation ratio, AUC0–24,ss |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 60 mg | “4.0” “[1.00–6.00]” | “116 (50.3)” | “241 (47.1)” | “168 (45.2)” | “4030” | “2.25 (57.5)” | “2.94 (51.0)” |
| 90 mg | “4.0” “[1.00–6.00]” | “213 (92.7)” | “460 (77.4)” | “322 (82.1)” | “7720” | “3.55 (34.7)” | “5.12 (41.3)” |
| 120 mg | “4.0” “[1.00–6.00]” | “276 (41.6)” | “541 (37.4)” | “384 (37.9)” | “9210” | “1.96 (19.6)” | “4.76 (43.1)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.1.2.6.3-8"></a>

### Posted steady-state AUC by dose in the registry results

| Dose, once daily | Participants analyzed | AUC0–24 at steady state, ng/mL*h, geometric mean | Geometric coefficient of variation |
| --- | --- | --- | --- |
| 30 mg | “5” | “1956” | “33.0” |
| 60 mg | “26” | “4014” | “46.2” |
| 90 mg | “6” | “7668” | “82.4” |
| 120 mg | “77” | “9163” | “38.1” |
| 150 mg | “2” | “12580” | “27.3” |
| 210 mg | “6” | “22439” | “47.2” |
| 300 mg | “6” | “25438” | “40.2” |

Source: [ClinicalTrials.gov NCT04505826 results](https://clinicaltrials.gov/study/NCT04505826?tab=results)

<a id="topic-2.1.2.6.3-9"></a>

### Effective half-life by dose during dose escalation

| Dose, once daily | t1/2eff, h, GeoMean | GeoCV% |
| --- | --- | --- |
| 30 mg | “54.7” | “(26.0)” |
| 60 mg | “63.4” | “(29.2)” |
| 90 mg | “72.7” | “(54.1)” |
| 120 mg | “68.8” | “(54.7)” |
| 150 mg | “61.6” | “(23.6)” |
| 210 mg | “57.3” | “(109.9)” |
| 300 mg | “51.0” | “(61.7)” |

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.3-10"></a>

### Time to peak concentration during dose escalation

> “OP-1250 is readily bioavailable with a median tmax ranging between 2 and 4 hours”
> “Dose-proportional increases in OP-1250 exposures (mean Cmax and AUC0–24) were observed across all evaluated doses after single and multiple doses”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-2.1.2.6.3-11"></a>

### Terminal half-life and peak-to-trough variability at the dose selection analysis

> “Mean terminal half-life (t1/2)=8 days, supporting once-daily dosing”
> “Steady-state plasma levels showed minimal peak-to-trough variability, allowing complete inhibition of the ER for the full dosing interval”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

<a id="topic-2.1.2.6.3-12"></a>

### Exposure at 90 mg and 120 mg in combination with ribociclib

> “Palazestrant doses of 90 mg and 120 mg had overlapping exposure when in combination with ribociclib”
> “Steady-state plasma concentrations at both 90 mg and 120 mg doses exceeded the predicted efficacious threshold”
> “There was no clinically significant difference in exposure between 90 mg and 120 mg doses.”

Source: [Lin et al. (2025b)](https://ir.olema.com/static-files/e0c71c44-768f-4c6c-910a-167adf046b97)

<a id="topic-2.1.2.6.3-13"></a>

### Plasma protein binding across species

> “Compound 21 is highly plasma protein-bound (>99%) across all species, including humans. Plasma free drug percentages in mouse/rat/dog/cyno/hu are 0.06/0.24/0.04/0.13/0.08, respectively.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-14"></a>

### Nonclinical oral half-life

> “Compound 21 is orally bioavailable and has low clearance and a long half-life in the mouse, rat, dog, and monkey”
> “The half-lives after a single oral dose in the mouse, rat, dog, and monkey were 10, 16, 106, and 34 h, respectively.”

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-15"></a>

### Nonclinical single oral dose pharmacokinetics

| Species | Oral dose, mg/kg | Tmax, h | T1/2, h | Oral bioavailability, F (%) |
| --- | --- | --- | --- | --- |
| Mouse | “5” | “1” | “10” | “72” |
| Rat | “5” | “1.5” | “16” | “55” |
| Dog | “10” | “1.5” | “106” | “89” |
| Monkey | “10” | “8” | “34” | “44.4” |

Source: [Ng et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163657/)

<a id="topic-2.1.2.6.3-16"></a>

### Brain and tumor concentrations in mice

> “OP-1250 demonstrated plasma exposures well above levels needed for complete ER saturation at Ctrough, robust brain penetrance with brain/plasma ratios >1, and tumor accumulation.”

Source: [Parisian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10911704/)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
